Placental abruption screening

Revision as of 15:15, 3 August 2020 by Dr.Rana (talk | contribs)
Jump to navigation Jump to search

Placental abruption Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Placental abruption from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Placental abruption screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Placental abruption screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Placental abruption screening

on Placental abruption screening

Placental abruption screening in the news

Blogs on Placental abruption screening

Directions to Hospitals Treating Placental abruption

Risk calculators and risk factors for Placental abruption screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Rana aljebzi, M.D.[2]

screeninig

  • First trimester (pregnancy-associated placental protein-A [PAPP-A])
  • second trimester (total hCG and alpha fetoprotein [AFP]) serum biochemistry were determined.
The two screening periods were compared for the prediction of a range of severe adverse perinatal outcomes (intrauterine growth restriction [IUGR], abruption, severe pre-eclampsia/HELLP syndrome, delivery < 32 weeks, or stillbirth).

References

Template:WH Template:WS